典晶生物医药科技（上海）有限公司 ELUMINEX BIOSCIENCES LIMITED Mediaroom - PR Newswire APAC

Search

典晶生物医药科技（上海）有限公司 ELUMINEX BIOSCIENCES LIMITED

Latest News

Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)

* EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R * Improvements in Visual Acuity and Retinal E...

2025-06-10 00:00 2017

Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations

SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a ...

2024-04-30 23:00 3074

Eluminex Biosciences Receives Scientific Recognition for its Recombinant Human Collagen (rhCIII) Biosynthetic Cornea (EB-301) Program to Treat Corneal Blindness

Awarded Honors at the American Society of Cataract and Refractive Surgery (ASCRS) andthe Associatio...

2023-05-16 23:00 2367

Eluminex Biosciences Closes $40+ Million Series B Financing to Continue the Development of Innovative Ophthalmic Assets and Recombinant Human Collagen Technology

SUZHOU, China and SAN FRANCISCO, Feb. 27, 2023 /PRNewswire/ -- Eluminex Biosciences (Suzhou) Limite...

2023-02-28 01:00 2521

Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301)

Initial Part A results to be presented at the upcoming American Society of Cataract and Refractive ...

2023-02-15 01:00 2295

Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings

* Purchase of Assets and Related Global Commercialization Rights for Oral 9- cis-Retinol (Zuretino...

2022-01-19 19:49 1923